5月27日 - ** 医疗设备制造商NeuroPace NPCE.O股价盘前下跌15%至15.02美元
** 该公司援引初步数据称，在一项为期两年的研究中，针对一组遗传性癫痫综合征的神经调节疗法未能在总体人群中达到主要疗效目标
** 该设备名为 RNS 系统，植入头骨后可持续监测脑电波，识别并干扰可能引发癫痫发作的异常活动。
** 然而，该装置在代表大多数参与者的一部分患者中显示出显著疗效--NPCE
** 美国已批准该设备用于治疗局灶性癫痫，这是一种仅影响一侧大脑和身体的癫痫发作类型。
** 截至上一交易日收盘，股价累计上涨约 58
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.